NICE to Charge up to $282,000 for New Drug Assessments

The UK’s National Institute of Health and Care Excellence (NICE) plans to start charging pharmaceutical companies new fees for each cost-effectiveness assessment for a new medicine beginning next year. The new fees could be up to $282,000! Find out more here. (Source: Zachary Brennan, RAPS, 10/3/16)

You might also be interested in:

PAI and BresMed Join Forces to Support Expanded Use of More… 07/22/2019
Biomarkers and Companion diagnostics: Payer Insights 09/26/2019
The Future of Personalised Medicine: The Role of Simulation… 01/25/2020
The Global Use of Medicine in 2019 and Outlook to 2023 01/29/2019
Applied Health Economics for Public Health Practice and Research 03/28/2019
Leveraging Technology to Reduce Costs in Clinical Trials 06/30/2019
The Growing Influence of the Institute of Clinical and… 11/21/2019